Global Deoxyribonucleic Acid (DNA) and Gene Chip (Microarrays) Market, By Product (Consumables, Instrumentation), Type (Oligonucleotide DNA Microarrays (DNA), Complementary DNA Microarrays (cDNA)), Application (Gene Expression, Cancer Diagnostics and Treatments, Drug Discovery, Genetics, SNP Analysis, Screening and Monitoring Of Patient Data During Clinical Trials, Proteomics, Toxicogenomics, Microbial Genotyping, Agricultural Biology, Environmental Control), End User (Academic and Research Institutes, Biotechnological and Pharmaceutical Companies, Research Laboratories) – Industry Trends and Forecast to 2030.
Get Exclusive Sample Copy of this Report Here
Deoxyribonucleic Acid (DNA) and Gene Chip (Microarrays) Market Analysis and Size
As per the Globocan 2020 statistics, there were around 467,965 new cancer cases in France, with 185,621 deaths. As per the Foundation de France, cancer affects more than 350,000 people yearly and kills close to 150,000, resulting in approximately one-third of all deaths. Deoxyribonucleic acid (DNA) and gene chip (microarrays) are increasingly gaining much importance in emerging economies and increasing awareness about them in remote areas. Thus, deoxyribonucleic acid (DNA) and gene chip (microarrays) are discovered to play a critical role in risk assessment and early diagnosis.
Data Bridge Market Research analyses that the deoxyribonucleic acid (DNA) and gene chip (microarrays) market, which was USD 13.24 billion in 2022, would rocket up to USD 36.74 billion by 2030, and is expected to undergo a CAGR of 13.6% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Deoxyribonucleic Acid (DNA) and Gene Chip (Microarrays) Market Scope and Segmentation
Report Metric
|
Details
|
Forecast Period
|
2023 to 2030
|
Base Year
|
2022
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
Segments Covered
|
Product (Consumables, Instrumentation), Type (Oligonucleotide DNA Microarrays (DNA), Complementary DNA Microarrays (cDNA)), Application (Gene Expression, Cancer Diagnostics and Treatments, Drug Discovery, Genetics, SNP Analysis, Screening and Monitoring Of Patient Data During Clinical Trials, Proteomics, Toxicogenomics, Microbial Genotyping, Agricultural Biology, Environmental Control), End User (Academic and Research Institutes, Biotechnological and Pharmaceutical Companies, Research Laboratories)
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific (U.S.), Abbott (U.S.), QIAGEN (Germany), PerkinElmer, Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Enzo Biochem, Inc. (U.S), Charles River Laboratories (U.S.), Agilent Technologies, Inc. (U.S.), Bruker (U.S.), Siemens (U.S.), General Electric (U.S.) Oxford Gene Technology IP Limited (U.K.), Gyros Protein Technologies AB (U.K.), Macrogen, Inc (South Korea)., BIONEER CORPORATION (South Korea)
|
Market Opportunities
|
|
Market Definition
DNA microarray is the technology widely used to evaluate the expression levels of thousands of genes together and all genes in a genome at the same time. Microarrays assist in diagnosing gene discovery, disease, toxicological research, and medicine development. DNA and gene chip is a combination of technologies used to simultaneously detect expression levels of at least ten thousand DNA sequences named genes using a slide with DNA spots attached to it.
Global Deoxyribonucleic Acid (DNA) and Gene Chip (Microarrays) Market Dynamics
Drivers
- Increasing Use of Biochips
The increasing demand for biochips is surging the demand of the market. These techniques could separate cancer cells from blood samples and allow major profiling of cancer cells' genes, assisting the medical helps to target tumors and carrying out treatments efficiently. Thus, this factor boosts the growth of the market.
- Increasing Collaborations between Market Players
The market is increased by huge research collaborations carrying out technical analysis of gene expression techniques—for instance, Illumina. Inc., the largest player in this field, agreed to include biobanking deals with Montreal Heart Institutes and Montreal Heart Institute in 2016. Illumina's products were widely used in genotyping the probes stored by these research institutions. Thus, this factor boosts market growth.
Opportunities
- Increasing Developments by Market Players
There have been increasing developments by major market players that have led to the market's growth. For instance, MyHeritage, a top global service for family history and DNA testing, announced a major expansion of the company's DNA product line with the launch of the MyHeritage DNA Health + Ancestry test in 2020. The company has its custom-designed new DNA chip through Illumina's Global Screening Array (GSA) to balance the requirements of genetic genealogy and health testing. Thus, these increasing developments led to the growth of the market.
Restraints/Challenges
- Complications of Microarrays
The most major complications of microarrays include the high cost of a single experiment, the huge number of probe designs based on sequences of low specificity, and the lack of control during the pool of analyzed transcripts. Also, the results are not always reproducible. Thus, this factor restricts the market growth.
This deoxyribonucleic acid (DNA) and gene chip (microarrays) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the deoxyribonucleic acid (DNA) and gene chip (microarrays) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
• In 2020, two major companies named Cardea Bio and Nanosens Innovations collaborated to launch a CRISPR-Cas9-based biosensor diagnostic device using a graphene transistor known as CRISPR-Chip.
Global Deoxyribonucleic Acid (DNA) and Gene Chip (Microarrays) Market Scope
The deoxyribonucleic acid (DNA) and gene chip (microarrays) market is segmented on the basis of product, type, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Consumables
- Instrumentation
Type
- Oligonucleotide DNA Microarrays (oDNA)
- Complementary DNA Microarrays (cDNA)
Application
- Gene Expression
- Cancer Diagnostics and Treatments
- Drug Discovery
- Genetics
- SNP Analysis
- Screening and Monitoring Of Patient Data During Clinical Trials
- Proteomics
- Toxicogenomics
- Microbial Genotyping
- Agricultural Biology
- Environmental Control
End User
- Academic and Research Institutes
- Biotechnological and Pharmaceutical Companies
- Research Laboratories
Deoxyribonucleic Acid (DNA) and Gene Chip (Microarrays) Market Regional Analysis/Insights
The deoxyribonucleic acid (DNA) and gene chip (microarrays) market is analyzed and market size insights and trends are provided by product, type, application and end user as referenced above.
The countries covered in the deoxyribonucleic acid (DNA) and gene chip (microarrays) market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the deoxyribonucleic acid (DNA) and gene chip (microarrays) market due to the strong base of healthcare facilities, increasing investment from major market players in the growth of advanced devices, and increasing number of processes relating to drug development. Also, the detection of some tumors, monitoring of biological response to cancer therapy, and an increasing number of research activities in this region boost the market growth
Asia-Pacific is expected to witness significant growth due to the rise in government initiatives to promote awareness, an increase in medical tourism, rising research activities in the region, a growing prevalence of cancer, and the increased demand for quality healthcare.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The deoxyribonucleic acid (DNA) and gene chip (microarrays) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for deoxyribonucleic acid (DNA) and gene chip (microarrays) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the deoxyribonucleic acid (DNA) and gene chip (microarrays) market. The data is available for historic period 2011-2021.
Competitive Landscape and Deoxyribonucleic Acid (DNA) and Gene Chip (Microarrays) Market Share Analysis
The deoxyribonucleic acid (DNA) and gene chip (microarrays) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to deoxyribonucleic acid (DNA) and gene chip (microarrays) market.
Some of the major players operating in the deoxyribonucleic acid (DNA) and gene chip (microarrays) market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Thermo Fisher Scientific (U.S.)
- Abbott (U.S.)
- QIAGEN (Germany)
- PerkinElmer, Inc. (U.S.)
- Merck KGaA (Germany)
- Bio-Rad Laboratories, Inc. (U.S.)
- Enzo Biochem, Inc. (U.S)
- Charles River Laboratories (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Bruker (U.S.)
- Siemens (U.S.)
- General Electric (U.S.)
- Oxford Gene Technology IP Limited (U.K.)
- Gyros Protein Technologies AB (U.K.)
- Macrogen, Inc (South Korea)
- BIONEER CORPORATION (South Korea)
SKU-